Also trades as: SHIEF (OTC) · $vol 0M
STX.L LSE
Shield Therapeutics plc
1W: +14.4%
1M: +7.2%
3M: -2.5%
YTD: -44.6%
1Y: -26.5%
3Y: -43.3%
5Y: -86.5%
£6.00 ($0.08)
-0.05 (-0.83%)
Weekly Expected Move ±12.0%
£5
£5
£6
£7
£7
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$25M
+92.5% ▲
5Y CAGR: +103.6%
Gross Profit
$11M
+162.4% ▲
5Y CAGR: +114.3%
Operating Income
-$18M
+42.6% ▲
Net Income
-$21M
+36.1% ▲
EPS (Diluted)
$-0.02
+36.7% ▲
EBITDA
-$17M
+45.3% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $10M | $2M | $5M | $13M | $25M |
| YoY Growth | +1344.6% | -85.4% | +262.0% | +138.0% | +92.5% |
| Cost of Revenue | $1M | $980K | $2M | $9M | $15M |
| Gross Profit | $9M | $539K | $2M | $4M | $11M |
| Gross Margin | 87.0% | 35.5% | 36.3% | 30.8% | 42.0% |
| R&D Expenses | $3M | $579K | $1M | $2M | $1M |
| SG&A Expenses | $6M | $20M | $27M | $37M | $27M |
| Operating Expenses | $8M | $20M | $28M | $35M | $38M |
| Operating Income | -$2M | -$20M | -$26M | -$31M | -$18M |
| Operating Margin | -20.7% | -1343.3% | -479.9% | -239.4% | -71.4% |
| Interest Expense | $1K | $8K | $334K | $820K | $3M |
| Income Before Tax | -$2M | -$20M | -$40M | -$32M | -$21M |
| Tax Expense | $744K | -$229K | $446K | $918K | $490K |
| Net Income | -$3M | -$19M | -$40M | -$33M | -$21M |
| Net Margin | -25.3% | -1272.9% | -735.5% | -254.4% | -84.5% |
| EPS (Diluted) | $-0.02 | $-0.09 | $-0.17 | $-0.04 | $-0.02 |
| EBITDA | $820K | -$18M | -$46M | -$30M | -$17M |
| Shares Outstanding | 121M | 204M | 233M | 723M | 905M |